Resistance of Candida species is a major problem in the management of Candida infection. This study investigated in vivo antifungal activities of several new imidazole and triazole derivatives in a C. albicans systemic infection. The efficacy of derivatives was determined against systemic infection by C. albicans in mice with cyclophosphamide-induced immunosuppression, and the antifungal activities of the synthesized compounds were evaluated in comparison with fluconazole. Compounds 3 and 8 had the highest efficacy with minimum inhibitory concentration (MIC) values of 0.5-1 μM against the C. albicans pathogen. In vivo activities in immunosuppressed mice were also greater than fluconazole. Furthermore, docking analysis was carried out to know the binding mode of imidazole and triazole derivatives to the CYP51 active site of C. albicans and dihydrofolate reductase as a valid antifungal target. The docking study found that the antifungal results are well correlated with docking results. ADMET and in silico physicochemical parameters were also performed. This study demonstrates that compounds 3 and 8 are potential antifungal candidates against the C. albicans pathogen.
CITATION STYLE
Emami, L., Jamshidzadeh, A., Khabnadideh, S., Pakshir, K., Jamshidi, M., Rahat, S., … Rezaei, Z. (2023). In Vivo Antifungal Activity and Computational Studies of Some Azole Derivatives against Candida Albicans. Journal of Chemistry, 2023. https://doi.org/10.1155/2023/7834474
Mendeley helps you to discover research relevant for your work.